One of England's integrated care systems proved the benefit of modern, cloud-telephony during the COVID-19 pandemic, and is now working with X-on on new ideas to support GPs and patients, following a roll-out to practices. Associate director of digital & technology Alicia Dunsby explains. 
Insilico Medicine ("Insilico"), a clinical-stage end-to-end generative artificial intelligence (AI)-driven drug discovery company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to INS018_055 for the treatment of Idiopathic Pulmonary Fibrosis (IPF). 
A new Artificial Intelligence (AI) innovation to help speed up MRI scanning planning time and alleviate pressure on radiology services has been launched into the UK by Canon Medical Systems. Auto Scan Assist utilises Deep Learning and Machine Learning to enhance diagnostic imaging of liver, prostate, and whole-spine examinations to achieve greater efficiencies in delivering patient services. 
Bayer announced the acquisition of the global strategic imaging AI platform and solutions provider Blackford Analysis Ltd. The acquisition is part of Bayer's strategy to drive innovation in radiology, including the development and adoption of AI within the clinical workflow, with the goal to ultimately improve patient care and advance Bayer’s position in digital medical imaging. Bayer AG and Google Cloud today announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-developed accelerators designed to run cutting-edge machine learning models and computationally-intensive workloads, to help accelerate and scale Bayer's quantum chemistry calculations. 
The start-up accelerator supports entrepreneurial and innovative teams that want to grow sustainably and successfully scale their business model. With a strong hands-on mentality and a lot of passion, the SpinLab team works to ensure that promising startups receive all the necessary resources as well as sufficient professional support for long-term success in the market. 
At the 2023 Annual J.P. Morgan Healthcare Conference, Owkin Co-founder and CEO Thomas Clozel, MD will outline how data is the future of medicine - from the development of new drugs to patient treatment decisions.
At 3pm (PST) on Tuesday the 10th of January at the Golden Gate Hotel, San Francisco, Thomas will discuss how finding the right treatment for every patient can only be achieved by the secure analysis of high-quality data, with data flowing freely yet securely between care and research.